Cabozantinib (XL184, BMS-907351)

Cabozantinib (XL184, BMS-907351)は、VEGFR2とc-Metの強力な幅広いスペクトル・チロシン・キナーゼ阻害剤で、 IC50 がそれぞれ 0.035 nM と 1.3 nMです。

価格 在庫  
USD 138 あり
USD 214 あり
USD 277 あり
USD 592 あり
USD 1256 あり

Cabozantinib (XL184, BMS-907351) 化学構造
分子量: 501.51



Quality Control & MSDS


  • Compare VEGFR Inhibitors
  • 研究分野



製品説明 Cabozantinib (XL184, BMS-907351)は、VEGFR2とc-Metの強力な幅広いスペクトル・チロシン・キナーゼ阻害剤で、 IC50 がそれぞれ 0.035 nM と 1.3 nMです。


c-Met Ret c-Kit Flt-1/3/4 Tie2
IC50 0.035 nM 1.3 nM 4 nM 4.6 nM 12 nM/11.3 nM/6 nM 14.3 nM [1]
In vitro試験 XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SNU-5  M3;KV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPoW|NyUUN3ME2gNVkhdk1? NV7pVGRoOjF7Mk[xPVE>
Hs746T  NFf3SXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvtfIR6UUN3ME25Mlkhdk1? NH3YT|EzOTl{NkG5NS=>
SNU-1  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTV{MkOgcm0> NYDKSGNCOjF7Mk[xPVE>
SNU-16 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzNEmgcm0> M3j6NFIyQTJ4MUmx
MDA-MB-231 M3X0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRSB4NEKxJI5O MUCyNVkzPjF7MR?=
U87MG M3HKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ToOWlEPTB;MUi1NUBvVQ>? NHLyOoIzOTl{NkG5NS=>
H441  Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnsTWM2OD1{MUewNEBvVQ>? NHrzcmwzOTl{NkG5NS=>
PC3 NYn1[5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jrbmlEPTB;MUC4NFAhdk1? NVKwdlVxOjF7Mk[xPVE>
MZ-CRC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRiB3IN88US=> Mn3GNlE1PzB7OUW=
TPC-1 NGC1UZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli2TWM2OD1yLkC2JEshOC5yMjFOwG0> NXfFOWx7OjF2N{C5PVU>

... Click to View More Cell Line Experimental Data

In vivo試験 XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. [1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]
臨床試験 XL184 is currently under Phase III study versus mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer (COMET-2).

プロトコル (参考用のみ)



細胞株 ST88-14, STS26T, and MPNST724
濃度 Dissolved in DMSO, final concentrations ~10 μM
反応時間 48 hours

Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.



動物モデル RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
製剤 Suspended at a concentration of 5 mg/mL in sterile saline or water
投薬量 ~60 mg/kg
投与方法 Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Cabozantinib (XL184, BMS-907351) SDF
分子量 501.51


CAS No. 849217-68-1
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (199.39 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

文献中の引用 (13)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related VEGFR 阻害剤

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506)は、VEGFR1、VEGFR2、VEGFR3、PDGFRβ、キット、RET</b、Raf-1のためのマルチターゲット阻害剤で 、 IC50がそれぞれ13 nM、4.2 nM、46 nM、 22 nM、 7 nM、 1.5 nM 、2.5 nMです。

  • Axitinib

    Axitinibは、マルチターゲット阻害剤で、 VEGFR1VEGFR2VEGFR3、 PDGFRβ 、c-Kit に作用する時、IC50 がそれぞれ 0.1 nM、0.2 nM、0.1-0.3 nM、 1.6 nM 、1.7 nMになる。

    Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120)は三重血管キナーゼ阻害剤、VEGFR1, VEGFR2, VEGFR3 を作用すると、 IC50 がそれぞれ 34 nM, 5 nM 、 5 nMとなる。Phase 2.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474)は、VEGFR2の強力な阻害剤で、IC50 が 40 nM。

  • Lenvatinib (E7080)

    Lenvatinib (E7080)は、VEGFR2とVEGFR3のマルチ目標とされたキナーゼ阻害剤で、IC50 がそれぞれ 4 nM と 5.2 nMです。


Tags: Cabozantinib (XL184, BMS-907351)を買う | Cabozantinib (XL184, BMS-907351)供給者 | Cabozantinib (XL184, BMS-907351)を購入する | Cabozantinib (XL184, BMS-907351)費用 | Cabozantinib (XL184, BMS-907351)生産者 | オーダーCabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID